Atrial Fibrillation Risk Genotype Add-On
The Atrial Fibrillation Risk Genotype Add-On queries SNPs robustly associated with AF susceptibility, stratifying inherited risk to inform rhythm surveillance intensity, risk-factor modification, and shared decision-making about anticoagulation thresholds. Results are genotypes and a risk classification, not a diagnosis;
1
Biomarkers
Blood (whole blood)
Sample
7–14 business days
Turnaround
No
Fasting
What is the AF Risk Genotype test?
The Atrial Fibrillation Risk Genotype Add-On is a targeted genetic panel that queries single-nucleotide polymorphisms robustly associated with atrial fibrillation susceptibility in large genome-wide association studies. It is ordered as an adjunct to clinical risk assessment in patients with a family history of AF, borderline clinical risk, or unexplained palpitations, and it complements rather than replaces electrocardiographic and structural cardiac evaluation. This test does not diagnose atrial fibrillation — that remains an ECG-based diagnosis — but stratifies inherited predisposition. Practitioners use the result to refine screening frequency, guide discussions about lifestyle and risk-factor modification, and inform threshold decisions for ambulatory rhythm monitoring or anticoagulation in patients with subclinical or low-burden paroxysmal AF. Because the genetic contribution is independent of age, blood pressure, and other acquired risk factors, the genotype can be particularly informative in younger patients or those with a strong family history.
What does the AF Risk Genotype test measure?
Genome-wide association studies have identified common single-nucleotide polymorphisms near genes implicated in cardiac ion channel function, structural remodelling, and developmental pathways (notably chromosome 4q25 near PITX2) that are robustly associated with atrial fibrillation risk across populations. These variants modulate susceptibility to AF through effects on atrial electrophysiology, fibrosis, and structural substrate, but environment, comorbidity, and other genetic factors combine to determine phenotype. The genetic architecture of AF is polygenic, so individual SNPs confer modest effect sizes and are aggregated into a risk score.
Genotyping common AF-associated SNPs stratifies inherited risk and may identify individuals who would benefit from earlier or more intensive rhythm surveillance and risk-factor modification. Because AF has a heritable component independent of traditional clinical risk factors, a genetic test can add discrimination in borderline-risk or family-history-positive patients. Results are not diagnostic — AF remains a clinical diagnosis — but inform personalised screening intervals and shared decision-making about anticoagulation thresholds in subclinical or paroxysmal AF.
Why is the AF Risk Genotype test ordered?
- Patients with a first-degree family history of atrial fibrillation, especially early-onset AF in a parent or sibling, to stratify inherited risk
- Individuals with unexplained palpitations or borderline pretest probability where a higher genetic risk would prompt extended ambulatory monitoring
- Younger patients (under 60 years) with lone AF or minimal structural heart disease, where genetic susceptibility may dominate acquired risk
- Shared decision-making discussions about anticoagulation threshold in patients with subclinical AF detected on implanted device or smartwatch, when genetic risk may tip the balance
- Personalised cardiovascular risk assessment in the context of a comprehensive cardiometabolic or longevity panel that includes polygenic risk scores
- Research or registry participation where AF genetic architecture is being studied, provided appropriate informed consent
Sample collection and turnaround
Sample type
Blood (whole blood)
Fasting required
No
Collection method
Venipuncture at patient service centre
Turnaround
7–14 business days
Collection notes
Phlebotomy at the draw site; whole blood collected into EDTA (purple-top) tube for genomic DNA extraction. Genotype is stable and does not change with time, diet, or medication, so no special preparation or timing is required.
Specimen requirements
One EDTA tube (typically 3–5 mL whole blood); DNA is extracted at the laboratory. Specimen identity must be confirmed with two independent identifiers. Boston Heart Diagnostics performs the genotyping; confirm specimen-handling and shipping requirements with the laboratory.
What can affect AF Risk Genotype results?
AF-associated SNPs were discovered and validated predominantly in European-ancestry cohorts; effect sizes and allele frequencies differ across populations, so risk algorithms may be less well calibrated in non-European ancestries and should be interpreted with caution.
AF genetics are polygenic, so a single SNP panel captures only part of heritable risk; environmental triggers, comorbidity, and unmeasured variants also contribute, meaning a low-risk genotype does not exclude AF and a high-risk genotype does not guarantee it.
As with all genetic tests, specimen identity must be rigorously controlled; a mislabelled sample yields results for the wrong individual, so chain-of-custody and two-identifier verification are critical.
Different laboratories interrogate different SNP sets and use proprietary risk algorithms; results are not directly comparable across platforms, and the clinician should note which panel and algorithm were used.
Hypertension, obesity, obstructive sleep apnoea, alcohol, and structural heart disease amplify genetic risk; the genetic result must be integrated with clinical risk factors, not interpreted in isolation.
What do AF Risk Genotype results mean?
Elevated
An elevated genetic risk classification (often reported as 'high risk' or top quintile/quartile) indicates that the patient carries a genotype associated with substantially increased AF susceptibility relative to the population. This warrants more intensive rhythm surveillance (for example, extended Holter or implantable loop recorder in symptomatic patients), aggressive management of modifiable risk factors (weight, blood pressure, alcohol, sleep apnoea), and a lower threshold for anticoagulation if subclinical AF is detected. It does not diagnose AF and should not prompt anticoagulation in the absence of documented arrhythmia.
Normal
An intermediate or population-average genetic risk means that common SNPs neither substantially elevate nor lower AF risk; clinical and environmental factors predominate. Standard rhythm surveillance and risk-factor management apply, guided by age, comorbidity, and symptoms rather than genotype.
Reduced
A low genetic risk classification (bottom quintile/quartile) suggests that common AF-associated variants contribute less to this individual's risk, though acquired factors and rare variants may still be important. It may provide reassurance in a patient with a family history but does not eliminate the need for clinical vigilance, especially in the presence of hypertension, structural heart disease, or other acquired risk factors.
Note: Results are genotypes, not a diagnosis. AF remains a clinical and ECG-based diagnosis; genetic risk informs screening intensity and shared decision-making but does not replace clinical assessment. Polygenic risk scores are probabilistic and population-relative, with limited sensitivity and specificity for individual prediction. Penetrance is incomplete, so a high-risk genotype does not guarantee AF, and a low-risk genotype does not exclude it. The panel's performance characteristics are best validated in European-ancestry populations; extrapolation to other ancestries should be done cautiously. Informed consent addressing genetic data privacy, potential psychological impact, and the exploratory nature of polygenic risk is essential.
Frequently asked questions
No. Atrial fibrillation is an electrocardiographic diagnosis. This genetic panel stratifies inherited susceptibility and informs screening intensity and shared decision-making, but it does not diagnose AF and should not prompt treatment in the absence of documented arrhythmia.
How to access the AF Risk Genotype test
The AF Risk Genotype reference page is free and open to all practitioners. Create a free practitioner account to see pricing, save tests to your list, and generate requisition forms. Verification takes 1–2 business days.
Create Free AccountAbout this page
Published: October 7, 2026
Last reviewed: October 7, 2026
- Roselli C, et al. Multi-ethnic genome-wide association study for atrial fibrillation. Nature Genetics. (2018)
- Khera AV, et al. Genome-wide polygenic scores for common diseases identify individuals with risk equivalent to monogenic mutations. Nature Genetics. (2018)
- January CT, et al. 2019 AHA/ACC/HRS focused update of the 2014 guideline for the management of patients with atrial fibrillation. Circulation. (2019)
- Lubitz SA, et al. Genetic risk prediction of atrial fibrillation. Circulation. (2017)
- Hindricks G, et al. 2020 ESC guidelines for the diagnosis and management of atrial fibrillation. European Heart Journal. (2021)
This content is for licensed healthcare practitioners only and does not constitute medical advice. Clinical decisions should be based on the full clinical picture and not on any single test result.
Related tests
metabolic diabetes
CMP
The Comprehensive Metabolic Panel is a 14-analyte serum chemistry panel simultaneously evaluating renal function (creatinine, BUN, eGFR), hepatic function (ALT, AST, total bilirubin, albumin, total protein), metabolic status (glucose, calcium), and electrolyte-acid-base homeostasis (sodium, potassium, chloride, bicarbonate) from a single fasting serum specimen.
cardiovascular
Lipid Panel
The Lipid Panel measures total cholesterol, LDL cholesterol, HDL cholesterol, triglycerides, non-HDL cholesterol, and VLDL cholesterol from a single fasting serum specimen, providing the foundational cardiovascular lipid risk profile for ASCVD risk stratification, lipid-lowering therapy initiation and monitoring, familial hypercholesterolaemia identification, and atherogenic dyslipidaemia…